Abstract: An example system according to the present invention can provide a more convenient system. A mobile terminal device includes an acquisition unit configured to acquire information specifying a bacterial strain and information specifying a sensitivity rate, and a specification unit configured to specify, using an antibiogram, information on one or a plurality of antimicrobial agents, each of the antimicrobial agents satisfying the sensitivity rate for the bacterial strain. The information on the antimicrobial agent includes a sensitivity rate of the antimicrobial agent, a spectrum score for the antimicrobial agent, and/or an AWaRe classification of the antimicrobial agent. The mobile terminal device includes a display unit configured to display a plurality of sensitivity rate candidates, and the sensitivity rate is selected, by a user, from among the plurality of sensitivity rate candidates.

Abstract: One or more of HLA gene primers selected from the group consisting of the following (1) to (3): (1) one or more HLA-G gene primers which are (1a) a first primer including the nucleotide sequence of SEQ ID NO. 1 and/or (1b) a second primer including the nucleotide sequence of SEQ ID NO. 3, (2) one or more HLA-E gene primers which are (2a) a first primer including the nucleotide sequence of SEQ ID NO. 5 and/or (2b) a second primer including the nucleotide sequence of SEQ ID NO. 7, and (3) one or more HLA-F gene primers which are (3a) a first primer including the nucleotide sequence of SEQ ID NO. 9 and/or (3b) a second primer including the nucleotide sequence of SEQ ID NO. 11.

Abstract: An object of the present invention is to provide an endodermal cell population for obtaining optimal somatic cells as cell therapy preparations. The endodermal cell population of the present invention has a reduced content proportion of undifferentiated cells in the cell population and contains endodermal cells differentiable into optimal somatic cells as cell therapy preparations. Further, a somatic cell derived from the endodermal cell population of the present invention has excellent therapeutic effects as a cell therapy preparation.

Abstract: The purpose of the present invention is to provide: a method for testing the aggravation risk for a person infected with the COVID-19 virus, the method allowing the use of urine as a test sample; a test kit for the method; and a companion diagnostic drug and an aggravation risk marker thereof. The present invention is a method that includes a step for determining the amount of liver fatty acid binding protein in urine sampled from a subject, and that tests the aggravation risk of SARS-CoV-2 infectious disease (COVID-19) on the basis of the quantitative determination result.

Abstract: A method for inducing differentiation into pancreatic ? cells includes: a step (a) of culturing endodermal cells, which have been induced to differentiate from pluripotent stem cells, in the presence of a bone morphogenetic protein (BMP) signaling inhibitor, and retinoic acid or a retinoic acid analog to induce differentiation into primitive gut tube (PGT) cells; a step (b) of culturing the primitive gut tube (PGT) cells to induce differentiation into pancreatic endocrine precursor (EP) cells; and a step (c) of culturing the pancreatic endocrine precursor (EP) cells to induce differentiation into pancreatic ? cells, in which the step (b) and the step (c) are performed in the absence of ascorbic acid.

Abstract: Provided is a transplantation device comprising a hydrogel in which insulin-secreting cells or pancreatic islets are enclosed, wherein the hydrogel is prepared by gelatinizing an alginic acid derivative by a chemical crosslinkage. Thus, a novel transplantation device is provided.

Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: Disclosed is a method for acquiring information on exacerbation risk of COVID-19, comprising measuring IgM antibody against S antigen of SARS-CoV-2 contained in a specimen collected from a subject infected with SARS-CoV-2 or a subject suspected of suffering from COVID-19, wherein a value obtained by the measurement of IgM antibody serves as an index of exacerbation risk of COVID-19 of the subject.

Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.

Abstract: An object of the present invention is to provide an endodermal cell population for obtaining optimal somatic cells as cell therapy preparations. The endodermal cell population of the present invention has a reduced content proportion of undifferentiated cells in the cell population and contains endodermal cells differentiable into optimal somatic cells as cell therapy preparations. Further, a somatic cell derived from the endodermal cell population of the present invention has excellent therapeutic effects as a cell therapy preparation.

Abstract: Disclosed is a method for assisting prediction of exacerbation of respiratory infection, comprising measuring a biomarker in a specimen collected from a subject suffering from a respiratory infection or a subject suspected of having a respiratory infection, wherein the biomarker is at least one selected from the group consisting of IFN?3, CCL17, CXCL11, IP-10, IL-6 and CXCL9, and a measured value of the biomarker is used as an index to predict exacerbation of the respiratory infection.

Abstract: A problem addressed by the present invention is to provide a method for producing pancreatic ? cells from endothermal cells that have been induced to differentiate from pluripotent stein cells, wherein the method allows the production of pancreatic ? cells of high quality, and to provide pancreatic progenitor (PP) cells, pancreatic endocrine precursor (EP) cells, and pancreatic ? cells produced by the above-mentioned method.

Abstract: A problem addressed by the present invention is to provide a method for producing primitive gut tube cells from endothermal cells that have been induced to differentiate from pluripotent stein cells, wherein the method allows the production of pancreatic ? cells of high quality. The present invention provides a method for producing primitive gut tube (PGT) cells comprising a step of culturing, in the absence of a bone morphogenetic protein (BMP) signaling inhibitor, endodermal cells that have been induced to differentiate from pluripotent stem cells.

Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: It is found that a nucleoside derivative represented by the following general formula (1) has an anti-viral activity and is less toxic to host cells. [in the formula, R1 represents a hydrogen or halogen atom, R2 represents a hydrogen or halogen atom, R3 represents a cyano group, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a halogen atom, or an azido group, R4 represents an amino group, a hydrogen atom, a halogen atom, or a hydroxy group, R5 represents a nitrogen atom or a methine group, R6 represents a hydrogen atom or a hydroxy group, and R7 represents a hydrogen atom or a hydroxy group].

Abstract: [Problem to be Solved] It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. [Solution] The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.

Abstract: It is found that a nucleoside derivative represented by the following general formula (1) has an anti-viral activity and is less toxic to host cells. [in the formula, R1 represents a hydrogen or halogen atom, R2 represents a hydrogen or halogen atom, R3 represents a cyano group, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a halogen atom, or an azido group, R4 represents an amino group, a hydrogen atom, a halogen atom, or a hydroxy group, R5 represents a nitrogen atom or a methine group, R6 represents a hydrogen atom or a hydroxy group, and R7 represents a hydrogen atom or a hydroxy group.

Abstract: The problem is to produce functional liver cells usable in testing the metabolism and toxicity of a drug, from pluripotent stem cells. The solution includes a method for producing highly functional liver cells using pluripotent stem cells, comprising, from pluripotent stem cells, acquiring primitive endoderm derived from the pluripotent stem cells by a process involving steps (A) and (B), from the primitive endoderm, acquiring liver precursor cells by a process involving step (C), and, from the liver precursor cells, acquiring the highly functional liver cells by a process involving step (D): (A) culturing under serum-free and feeder-free conditions; (B) culturing in the presence of albumin and at least one kind of cytokine; (C) culturing in the presence of SHH or an SHH agonist and at least one kind of cytokine; and (D) culturing and maturing in the presence of at least one kind of cytokine.

Abstract: An object of the present invention is to provide a composition for promoting interferon ? production, which contains an active ingredient exhibiting an effect of promoting interferon ? production with respect to BDCA3 DC, and a production method therefor. The present invention relates to (1) a composition for promoting interferon ? production, which contains a bacterial cell, a bacterial component, or a culture of lactic acid bacteria capable of being cultured under stress conditions, as an active ingredient, and (2) a method for producing a composition for promoting interferon ? production, which includes culturing lactic acid bacteria capable of being cultured under stress conditions so as to obtain a bacterial cell, a bacterial component, or a culture of the lactic acid bacteria.